A Phase 1 interventional study of 0.76% Sodium Monofluorophosphate Dentifrice and 0.454% Stannous Fluoride Dentifrice in Gingivitis, sponsored by Procter and Gamble. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Procter and Gamble · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.
Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 1, and was the 18th registered.
631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.
Browse Gingivitis studies →1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:
Colgate Palmolive
Ages 60+ · Healthy volunteers
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 135 is above the median of 66 across 507 interventional studies indexed under Gingivitis.
Median enrollment 115 across the 23 interventional studies. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 23 have an industry lead sponsor. The 6 most frequent:
Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
22 studies in Gingivitis by Procter and Gamble: none open now, 2 under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 22 studies in Gingivitis by Procter and Gamble, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 1, and was the 20th registered.
Procter and Gamble’s Gingivitis studies by the year they started, since 2009.
1 of the studies testing Tin Fluorides in Gingivitis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07807397Colgate PalmoliveOral Hygiene Assistance Training Program | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing Tin Fluorides in Gingivitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Procter and Gamble’s 22 in Gingivitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is to assess the causal effect of oral hygiene intervention on gingivitis and systemic biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.76% sodium monofluorophosphate
Drug: 0.76% Sodium Monofluorophosphate Dentifrice
0.454% stannous fluoride
Drug: 0.454% Stannous Fluoride Dentifrice
0.454% stannous fluoride
Drug: 0.454% Stannous Fluoride Dentifrice
Brush two times a day for 1 minute with manual toothbrush
Brush two times a day for 1 minute with manual toothbrush
Brush two times a day for 2 minutes with electric toothbrush
Number Bleeding Sites
Total number of bleeding sites
Time frame: 4 months
Started Apr 2025 (actual). Primary completion is estimated for Oct 2025, 6 months after the start.
Of 11 phase 1 interventional studies under Gingivitis, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 7. This study's planned 6 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tin Fluorides